Lilly secures another myelofibrosis option via $1.5B deal for JPM-founded Calytrix

Eli Lilly booth at ASCO 2026
Lilly already has a myelofibrosis asset in its pipeline courtesy of its acquisition of Ajax in April. (Darren Incorvaia)

Eli Lilly has added another myelofibrosis (MF) play to its pipeline courtesy of a $1.5 billion deal for Massachusetts biotech Calytrix Bio.

The prize for Lilly is a biparatopic antibody for mutant calreticulin (mCALR)-driven essential thrombocythemia (ET) and MF, which are both rare blood cancers. Calytrix has touted the preclinical antibody as a way to deliver “disease-modifying pan-mutant activity, with a safety and convenience profile that supports early intervention and long-term treatment.”

While current treatments for ET and MF primarily manage symptoms and complications, Calytrix spied an opportunity for a precision therapy targeting the CALR mutation that drives the disease.

Under the deal, Calytrix’s shareholders could receive up to $1.5 billion cash spread across upfront and milestone payments—although the companies didn’t offer a detailed breakdown of the financials.

Lilly already has an MF asset in its pipeline courtesy of the phase 1-stage type II JAK2 inhibitor AJ1-11095, which was the focus of the Big Pharma’s $2.3 billion deal for Ajax Therapeutics in April. That bet appeared to pay off two months later when 70% of patients achieved a best response of at least a 35% reduction in spleen volume in early results from a phase 1 study.

In a note to investors this morning, Citi analysts suggested that Calytrix’s preclinical asset was a good strategic fit alongside AJ1-11095, as the newly acquired candidate targets the disease-driving clone rather than downstream JAK signaling.

“The biparatopic design targets both major mCALR mutation types, which together are found in roughly one-quarter of ET and primary MF patients,” the analysts noted. “While scientifically attractive, the program remains preclinical, and the safety bar will be particularly high in indolent ET.”

“An mCALR-specific antibody could be evaluated alone or potentially alongside a JAK2 inhibitor, although combination strategy, dosing and the ability to reverse established marrow fibrosis remain unproven,” the analysts concluded.

Calytrix was built last year by J.P. Morgan’s life sciences venture capital arm with a mission to develop disease-modifying therapies for patients living with myeloproliferative neoplasms (MPNs). 

“Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms,” the biotech’s CEO Brad Prosek said in a Nov. 16 release. 

“From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF,” Prosek added. “We look forward to Lilly advancing the program through the clinic and exploring its potential to benefit patients across the disease spectrum.”

The Calytrix acquisition caps of a hectic year of buyouts for Lilly. Fueled by sales of its GLP-1 drugs, the company has inked a series of takeovers and licensing pacts, penning multibillion-dollar deals with biotechs including AtaiBeckley, Centessa Pharmaceuticals and Kelonia Therapeutics.